Huntington's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Huntington's Disease, including details on genetics, causes, symptoms, treatment.

Volume 1 (2005), Issue 3 (March)

1. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.
   Neurogenetics, 6(1): 25-8. [Abstract] [Full-text]
2. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure.
   Hum Mol Genet, 14(6): 765-74. [Abstract] [Full-text]
3. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.
   Proc Natl Acad Sci U S A, 102(10): 3777-81. [Abstract] [Full-text]
4. Yugoslav HD phenocopies analyzed on the presence of mutations in PrP, ferritin, and Jp-3 genes.
   Int J Neurosci, 115(2): 299-301. [Abstract] [Full-text]
5. A meta-analytic review of verbal fluency deficits in Huntington's disease.
   Neuropsychology, 19(2): 243-52. [Abstract] [Full-text]
6. BAG-1 associates with the polyglutamine-expanded huntingtin aggregates.
   Neurosci Lett, 378(3): 171-5. [Abstract] [Full-text]
7. Alterations in dopamine and benzodiazepine receptor binding precede overt neuronal pathology in mice modelling early Huntington disease pathogenesis.
   Brain Res, 1039(1): 14-21. [Abstract] [Full-text]
8. Early Huntington's disease affects movements in transformed sensorimotor mappings.
   Brain Cogn, 57(3): 236-43. [Abstract] [Full-text]
9. (Mis)alignments in counseling for Huntington's Disease predictive testing: clients' responses to reflective frames.
   J Genet Couns, 14(1): 29-42. [Abstract] [Full-text]
10. A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease.
    Eur J Neurosci, 21(4): 855-70. [Abstract] [Full-text]
11. Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease.
    J Neurol Sci, 231(1): 57-66. [Abstract] [Full-text]
12. Interrater agreement in the assessment of motor manifestations of Huntington's disease.
    Mov Disord, 20(3): 293-7. [Abstract] [Full-text]
13. Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease.
    Mov Disord, 20(3): 371-7. [Abstract] [Full-text]
14. Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia.
    Ann Neurol, 57(4): 520-5. [Abstract] [Full-text]
15. Critical periods of suicide risk in Huntington's disease.
    Am J Psychiatry, 162(4): 725-31. [Abstract] [Full-text]

© 2005-2008 Huntington's Disease Research Today. All Rights Reserved.